CoChat

Reducing the toxicity of anticancer therapy: new strategies

Open access
Griggs, Jennifer J · 1998 · Leukemia Research

The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.

Abstract

Cytoprotective agents offer opportunities to reduce the treatment-related toxicity of anticancer therapy and perhaps to increase the dose and dose intensity of radiation and chemotherapy. One such agent is amifostine, an organic thiophosphate. Amifostine selectively protects normal tissues and provides broad-spectrum protection for a variety of organs while remaining minimally toxic. Clinical studies have demonstrated that amifostine protects against myelotoxicity, nephrotoxicity, neurotoxicity, mucositis and esophagitis in patients treated with alkylating and platinum agents, paclitaxel and radiation therapy. In addition, preclinical studies suggest the possibility of protection against anthracycline-induced cardiotoxicity and radiation- and chemotherapy-induced mutagenicity. Preclinical and clinical studies have not demonstrated any diminution of antitumor efficacy. Amifostine is well tolerated in doses of 740 or 910 mg/m2. The most common side effects requiring treatment are transient hypotension, which responds to intravenous fluids, and nausea and vomiting, effectively treated with 5-HT3 antagonists and dexamethasone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0145-2126(98)00036-8

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Research works printed but not linked: 2

  1. Yang JL, Fernandes DJ, Speicher L, Capizzi RL. Biochemical determinants of the cytoprotective effect of amifostine (meeting abstract). Proc Ann Meet Am Assoc Cancer Res 1995;36:1725.
  2. Yuhas JM, Culo F. Selective inhibition of the nephrotoxicity [28

Cited by

See all 50

Metadata

Authors
Griggs, J. J.
Affiliations
University of Rochester Medicine (US)
Corresponding author
Griggs, Jennifer J
Venue
Leukemia Research
Publisher
Elsevier BV
Published
1998-05
Volume
22
Pages
S27-S33
ISSN
0145-2126 (ISSN-L)
OpenAlex
W2023645569
Cited by
48
References
35
Citations by year
2026: 1 · 2025: 3 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 3 · 2013: 2 · 2012: 2
FWCI
2.81
Type
journal article
Language
en
Open access
Licence
Locations
  • Leukemia Research (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Chemotherapy-induced organ toxicity mitigation
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
  • Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
Keywords
amifostine, cytoprotective agents, chemotherapy toxicity, radiation toxicity, myelosuppression, nephrotoxicity, neurotoxicity, mucositis, esophagitis, alkylating agents, platinum agents, paclitaxel, anthracycline cardiotoxicity, mutagenicity, dose intensity, thiophosphates
MeSH terms
Antineoplastic Agents, Dose-Response Relationship, Drug, Amifostine, Humans, Neoplasms, Survival Rate, Treatment Outcome, Cytoprotection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reducing the toxicity of anticancer therapy: new strategies. https://app.cochat.ai/papers/10.1016/s0145-2126(98)00036-8
The paper
Griggs, J. J. (1998). Reducing the toxicity of anticancer therapy: new strategies. Leukemia Research. https://doi.org/10.1016/s0145-2126(98)00036-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.